Annual report pursuant to Section 13 and 15(d)

Basis of Presentation - Additional Information (Detail)

v3.20.1
Basis of Presentation - Additional Information (Detail)
$ / shares in Units, $ in Thousands
12 Months Ended
Nov. 05, 2019
USD ($)
$ / shares
shares
Oct. 29, 2019
USD ($)
$ / shares
shares
May 10, 2019
shares
May 09, 2019
shares
Nov. 09, 2018
USD ($)
Dec. 05, 2017
USD ($)
Aug. 08, 2017
USD ($)
Apr. 18, 2017
USD ($)
Dec. 31, 2019
USD ($)
$ / shares
shares
Dec. 31, 2018
USD ($)
shares
Dec. 31, 2017
USD ($)
Oct. 31, 2019
$ / shares
Mar. 31, 2019
USD ($)
May 10, 2018
shares
May 09, 2018
shares
Basis Of Presentation [Line Items]                              
Reverse stock split ratio     0.2                        
Description of reverse stock split                 At the Company’s annual meeting of stockholders on May 9, 2018 (the “2018 Annual Meeting”), the Company’s stockholders approved an amendment to its Restated Certificate of Incorporation to effect a reverse stock split of its common stock, at a ratio ranging from one-for-five to one-for-fifteen, with the final ratio to be determined by the Company’s board of directors (the “Board”). Immediately after the 2018 Annual Meeting, the Board approved a one-for-five (1:5) reverse stock split of the outstanding shares of the BIOLASE common stock. On May 10, 2018, the Company filed an amendment (the “Fourth Amendment”) to its Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the reverse stock split and to reduce the authorized shares of common stock from 200,000,000 shares to 40,000,000 shares. Except as the context otherwise requires, all current and prior year share numbers (including common stock warrants) and share price amounts (including exercise prices and closing market prices) contained in these audited financial statements and notes thereto reflect the one-for-five reverse stock split. Additionally, in 2018 the Company recorded a reclassification of $0.1 million between common stock and additional paid-in capital, equal to the reduction in par value.            
Common stock, shares authorized | shares     40,000,000 200,000,000         40,000,000 40,000,000       40,000,000 200,000,000
Reclassification of common stock and additional paid-in capital                   $ 100          
Loss from operations                 $ 15,621 20,885 $ 18,038        
Proceeds from equity offering, net of expenses           $ 11,400 $ 9,500 $ 10,200              
Borrowings under lines of credit                   $ 3,696          
Shares issued, price per share | $ / shares                       $ 0.5750      
Temporary equity preferred stock, shares issued | shares                 70,000 0          
Proceeds from equity offerings                 $ 9,171   $ 21,761        
Net proceeds from issuance of offering and private placement   $ 8,200                          
Working capital                 14,700            
Cash and cash equivalents, including restricted cash                 6,100            
Net accounts receivable                 $ 8,760 $ 11,112          
Series E Convertible Preferred Stock                              
Basis Of Presentation [Line Items]                              
Shares issued, price per share | $ / shares                 $ 57.50            
Temporary equity preferred stock, shares issued | shares                 69,565            
Convertible preferred stock, shares issued upon conversion | shares   100             100            
Convertible preferred stock, conversion price per share | $ / shares   $ 0.5750             $ 0.5750            
Underwritten Public Offering                              
Basis Of Presentation [Line Items]                              
Proceeds from equity offerings   $ 4,200                          
Underwritten Public Offering | Common Stock                              
Basis Of Presentation [Line Items]                              
Shares issued | shares   7,820,000                          
Shares issued, price per share | $ / shares $ 0.5750 $ 0.5750                          
Over-Allotment Option                              
Basis Of Presentation [Line Items]                              
Shares issued | shares 1,173,000                            
Shares issued, price per share | $ / shares $ 0.5750                            
Gross proceeds from issuance of equity $ 600                            
Private Placement                              
Basis Of Presentation [Line Items]                              
Gross proceeds from issuance of convertible preferred stock   $ 4,000                          
Private Placement | Series E Convertible Preferred Stock                              
Basis Of Presentation [Line Items]                              
Shares issued, price per share | $ / shares   $ 57.50             $ 57.50            
Temporary equity preferred stock, shares issued | shares   69,565             69,565 69,565          
Convertible preferred stock, shares issued upon conversion | shares                 69,565            
Gross proceeds from issuance of convertible preferred stock   $ 4,000                          
SWK Funding LLC                              
Basis Of Presentation [Line Items]                              
Borrowings under lines of credit         $ 12,500         $ 12,500          
Line of credit facility, maximum borrowing capacity                         $ 12,500    
Western Alliance | Business Financing Agreement                              
Basis Of Presentation [Line Items]                              
Line of credit facility, maximum borrowing capacity                   $ 6,000          
Minimum                              
Basis Of Presentation [Line Items]                              
Reverse stock split ratio       0.2                      
Maximum                              
Basis Of Presentation [Line Items]                              
Reverse stock split ratio       0.067                      
Maximum | Over-Allotment Option                              
Basis Of Presentation [Line Items]                              
Option to purchase additional common stock granted | shares 1,173,000 1,173,000